jnj-39393406 jnj-39393406 jnj-39393406 is an experimental medication which is under development by janssen pharmaceutica, a division of johnson & johnson, for the treatment of depressive disorders and smoking withdrawal. it acts as a selective positive allosteric modulator of the α7 nicotinic acetylcholine receptor (nachr). it does not act on the α4β2 or α3β4 nachrs or the serotonin 5-ht3 receptor, and does not interact with a panel of 62 other receptors and enzymes. the drug has been found to lower the agonist and nicotine threshold for activation of the α7 nachr by 10- to 20-fold and to increase the maximum agonist response of the α7 nachr by 17- to 20-fold. jnj-39393406clinical dataroutes ofadministrationby mouthdrug classantinicotinicidentifiers iupac name 3--5-pyridin-4-yl-1,2,4-triazol-1-yl]-n,n-dimethylpropanamide cas number953428-73-4pubchem cid16755766chemspider28424208uniit930sou82pchemblchembl3545291chemical and physical dataformulac19h18f2n6o3molar mass416.389 g·mol−13d model (jsmol)interactive image smiles cn(c)c(=o)ccn1c(=nc(=n1)nc2=cc3=c(c=c2)oc(o3)(f)f)c4=cc=nc=c4 inchi inchi=1s/c19h18f2n6o3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11h,7,10h2,1-2h3,(h,23,25)key:iurmhzbqeynqoh-uhfffaoysa-n as of february 2018, jnj-39393406 is in phase ii clinical trials for both depressive disorders and smoking withdrawal. it was also under investigation for the treatment of schizophrenia and alzheimer's disease, but development for these indications was discontinued.